Clinical trial
Comparison of Lanreotide Autogel® and Sandostatin LAR Depot in the Treatment of…
NCT00092287 · Ipsen, Industry · Terminated
Key facts
| NCT number | NCT00092287 |
|---|---|
| Title | Comparison of Lanreotide Autogel® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome |
| Official title | A Phase III, Prospective, Multicenter, Randomized, Open, Parallel Group Comparison of Lanreotide Autogel® (90 and 120 mg) Administered by Deep Subcutaneous Injection Every Four Weeks, With Sandostatin LAR Depot (20 and 30 mg) Administered by Intramuscular Injection, Every Four Weeks for Six Months… |
| Lead sponsor | Ipsen, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Malignant Carcinoid Syndrome |
| Intervention type | Drug |
| Interventions | lanreotide Autogel (somatostatin analogue), Sandostatin long acting release (LAR) Depot (somatostatin analogue) |
| Enrollment | 4 |
| Start date | Jul 1, 2004 |
| Completion | Oct 1, 2004 |
| First posted | Sep 27, 2004 |
| Last update posted | Apr 30, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: